MedPath

KAINOS MEDICINE INC

KAINOS MEDICINE INC logo
πŸ‡ΊπŸ‡ΈUnited States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:2

Trial Phases

2 Phases

Phase 1:2
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)β€’ Click on a phase to view related trials

Phase 1
2 (66.7%)
Phase 2
1 (33.3%)

Trial to Evaluate the Efficacy and Safety of KM-819 Treatment to Slow the Progression of Multiple System Atrophy (MSA)

Phase 2
Recruiting
Conditions
Multiple System Atrophy
Interventions
Drug: Placebo
First Posted Date
2023-01-25
Last Posted Date
2024-05-07
Lead Sponsor
Kainos Medicine Inc.
Target Recruit Count
78
Registration Number
NCT05695378
Locations
πŸ‡°πŸ‡·

CHA Bundang Medical Center, CHA University, Seongnam-si, Gyeonggi-do, Korea, Republic of

Phase I, KM-819 in Healthy Subjects for Parkinson's Disease

Phase 1
Completed
Conditions
Parkinson's Disease
Interventions
Drug: Placebo
First Posted Date
2017-01-18
Last Posted Date
2020-04-13
Lead Sponsor
Kainos Medicine Inc.
Target Recruit Count
88
Registration Number
NCT03022799
Locations
πŸ‡°πŸ‡·

CHA Bundang Medical Center, CHA University, Seongnam, Gyeonggi-do, Korea, Republic of

Single Ascending Dose (SAD)/Multiple Ascending Dose(MAD) Safety/Pharmacokinetic (PK) Study of KM-023

Phase 1
Completed
Conditions
Human Immunodeficiency Virus
Interventions
Drug: Placebo for KM-023
First Posted Date
2011-05-05
Last Posted Date
2012-07-26
Lead Sponsor
Kainos Medicine Inc.
Target Recruit Count
83
Registration Number
NCT01348516
Locations
πŸ‡°πŸ‡·

Clinical Trials Center, Seoul National University Hospital, Seoul, Korea, Republic of

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

Β© 2025 MedPath, Inc. All rights reserved.